BPC-157 vs TB-500: Which Is Right for You?
Neither BPC-157 nor TB-500 is FDA-approved; both were recommended for compounding by an 8–6 FDA advisory vote on July 23, 2026 that the FDA has not adopted, and both rest mainly on animal research.
Side-by-side comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a gastric protein (15 aa) | Marketed as thymosin beta-4 version/fragment |
| Human evidence | Small pilots only | None for the product as sold |
| FDA status | Not approved | Not approved |
| July 2026 PCAC vote | 8–6 (1 abstention) | 8–6 (1 abstention) |
| Sport | Prohibited | Prohibited |
| Approved human dose | None | None |
Complete comparison (2026)
Key takeaways
- Advisory votes are non-binding.
- FDA staff recommended against both.
- Products online are research chemicals, not drugs.
What are BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in a human gastric protein; it has been studied mainly in rodents for tissue repair and is not FDA-approved for any use.
TB-500 is a synthetic peptide marketed as a version or fragment of thymosin beta-4, a naturally occurring 43-amino-acid protein that binds actin and is involved in cell migration and wound repair; it is not FDA-approved.
Mechanism differences
BPC-157: angiogenesis and growth-factor signaling in animal models. TB-500/thymosin beta-4: actin binding, cell migration.
Effectiveness
No adequately powered human trials for either product in injury recovery.
Side effect profiles
Human safety data are insufficient for both; unregulated supply adds contamination and mislabeling risk.
Dosing & administration
There is no established human dose for either.
Cost
No legal prescription market yet for either.
FDA & regulatory status
Not approved. Compounding requires FDA acceptance of the committee recommendation and rulemaking.
Who should choose which
Neither has an evidence base that supports choosing one over the other for a health purpose.
What the evidence does not show
- Efficacy in humans.
- Long-term safety.
Frequently asked questions
Are BPC-157 and TB-500 legal?
Neither is FDA-approved. FDA advisers voted in July 2026 to recommend allowing compounding, but the FDA has not adopted it.
What is the difference between BPC-157 and TB-500?
BPC-157 derives from a gastric protein; TB-500 is marketed as a version of thymosin beta-4. Both are mostly studied in animals.
References
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
- FDA Panel Backs 6 Peptides for Compounding
- BPC-157 — PubChem compound summary (CID 9941957)
- beta-Thymosins
- Thymosin beta 4 and the eye: the journey from bench to bedside
- Thymosin beta-4 — PubChem compound summary (CID 45382195)
Find a clinic
Our clinic directory lists only clinics whose address and services we confirmed on their own websites, with the date we checked.